NEW YORK and MELBOURNE, Australia, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today
announced that recent meetings held with the United States Food and Drug Administration (FDA) support its planned regulatory
filing for commercialization of remestemcel-L in pediatric patients with steroid refractory acute graft versus host disease
(aGVHD).
Mesoblast gained agreement from the FDA on the proposed chemistry and manufacturing for commercialization. The FDA also provided
guidance on the presentation of data from the completed 55-patient Phase 3 trial and the 241-patient Expanded Access Program to be
included in the filing for the proposed indication. In the Phase 3 trial, Mesoblast met the pre-specified primary endpoint of
improved Day 28 overall response and improved responder survival through Day 180.
Mesoblast plans to initiate the submission of the BLA with the FDA in early 2019 for the use of remestemcel-L in treating aGVHD
in children. There are currently no approved products in the United States for aGVHD.
Mesoblast owns all commercial rights to remestemcel-L for all territories excluding Japan.
In Japan, Mesoblast’s licensee, JCR Pharmaceuticals Co. Ltd., is marketing TEMCELL®1 HS. Inj. for the treatment of
aGVHD in children and adults. Mesoblast receives royalty income on sales of TEMCELL in Japan as well as milestone payments.
In North America and EU5 countries, Mesoblast estimates that the addressable market opportunity is in excess of $US700 million
per annum.
About Mesoblast
Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company
has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates with three
product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to
degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from
the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses
from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the need
for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian
Securities Exchange (MSB) and on the Nasdaq (MESO). www.mesoblast.com
1. TEMCELL® HS Inj. is the registered trademark of JCR Pharmaceuticals Co. Ltd.
Forward-Looking Statements
This announcement includes forward-looking statements that relate to future events or our future financial performance and involve
known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or
achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by
these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a
guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking
statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements
about the timing, progress and results of Mesoblast’s preclinical and clinical studies; Mesoblast’s ability to advance product
candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals;
and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with
our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause
Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by
such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any
obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future
developments or otherwise.
For further information, please contact:
Julie Meldrum
Schond Greenway
Corporate Communications Investor
Relations
T: +61 3 9639
6036
T: +1 212 880 2060
E: julie.meldrum@mesoblast.com
E: schond.greenway@mesoblast.com
